United States //   News Releases

News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary FDA Classifies Previous Endologix AFX Safety Notice as Class I Recall
IRVINE, Calif. --(BUSINESS WIRE)--Oct. 5, 2018-- Endologix® Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has received notice that the U.S. Food and Drug Administration ( FDA ) has classified a voluntary recall action that
View HTML
Toggle Summary Endologix Announces Third Quarter Preliminary Revenue Results and Raises Low End of 2018 Revenue Guidance Range
The Company provides teleconference and webcast details for Investor Meeting IRVINE, Calif. --(BUSINESS WIRE)--Oct. 2, 2018-- Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the third
View HTML
Toggle Summary Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
IRVINE, Calif. --(BUSINESS WIRE)--Aug. 23, 2018-- Endologix , Inc. (Nasdaq: ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced the grant of inducement equity awards to three newly appointed executives (together, the “Awardees”).
View HTML
Toggle Summary Endologix to Host Investor Meeting on October 2, 2018
IRVINE, Calif. --(BUSINESS WIRE)--Aug. 23, 2018-- Endologix, Inc. (Nasdaq:ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it will host a meeting for financial analysts and investment professionals at 4:15 p.m.
View HTML
Toggle Summary Endologix Appoints Jeffrey S. Brown as Chief Operations Officer
IRVINE, Calif. --(BUSINESS WIRE)--Aug. 15, 2018-- Endologix, Inc. (Nasdaq:ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed Jeffrey S. Brown as the Company’s Chief Operations Officer, effective as of
View HTML
Toggle Summary Endologix Reports Second Quarter 2018 Financial Results
IRVINE, Calif. --(BUSINESS WIRE)--Aug. 9, 2018-- Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the second quarter ended June 30, 2018. The Company reported global revenue of $44.7 million in the second
View HTML
Toggle Summary Endologix, Inc. to Announce Second Quarter 2018 Financial Results on August 9, 2018
IRVINE, Calif. --(BUSINESS WIRE)--Jul. 16, 2018-- Endologix , Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the second quarter of fiscal year 2018 after the market close on Thursday, August 9,
View HTML
Toggle Summary Endologix Reports Positive 1-Year Results from the Ovation® LUCY Study
Presented in Late-Breaking Session at the Society for Vascular Surgery Annual Meeting IRVINE, Calif. --(BUSINESS WIRE)--Jun. 28, 2018-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced 1-year results from the LUCY (Evaluation of Fema L
View HTML
Toggle Summary Endologix Appoints Jeffry Fecho as Chief Quality Officer
IRVINE, Calif. --(BUSINESS WIRE)--Jun. 25, 2018-- Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed Jeffry Fecho as the Company’s Chief Quality Officer, effective as of June
View HTML
Toggle Summary Endologix Appoints John Onopchenko as Chief Executive Officer
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed John Onopchenko as the Company's Chief Executive Officer, effective immediately.
View HTML
Toggle Summary Endologix Reports First Quarter 2018 Financial Results
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the first quarter ended March 31, 2018 . "Our top-line performance during the first quarter reflects slightly
View HTML
Toggle Summary Endovascular Aneurysm Sealing (EVAS) with Nellix System Associated with Higher Survival than Traditional Endovascular Aneurysm Repair (EVAR) in New Study
Results Presented Today in Late-Breaking Aortic Trials Session at Charing Cross International Symposium IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced the results of a study, which was
View HTML
Toggle Summary Endologix, Inc. to Announce First Quarter 2018 Financial Results on May 2, 2018
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix , Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2018 after the market close on Wednesday, May 2, 2018 .
View HTML
Toggle Summary Endologix Reports Positive Results from Global ENCORE Analysis with Polymer Endovascular Aneurysm Repair (EVAR) Using Ovation Abdominal Stent Graft Systems
Company to Host Investor Conference Call on March 20, 2018 at 8:30 a.m. ET IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced the first results from ENCORE, a pooled, global analysis of several
View HTML
Toggle Summary Endologix, Inc. Announces Enrollment of the First Patient in EVAS2 IDE Clinical Study of the Nellix® EndoVascular Aneurysm Sealing System
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix , Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the first patient was treated in the EVAS2 IDE Confirmatory Clinical Study of the investigational Nellix® EndoVascular Aneurysm Sealing
View HTML